The study is expected to be completed in Q4, 2024.  Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Division of Hematology/HERM, Karolinska UniversityHospital Huddinge. Analysis of main blood markers takes place at the Central Laboratory, Karolinska UniverSite Hospital Solna, NKS. In accordance with the treatment schedule, OsteoDex is given every two weeks. The inclusion criteria include adult MM patients with relapsed/treatment-resistant disease, who have received 1-3 prior lines of therapy. The primary objective is to confirm safety and tolerability. Secondary objective is to determine treatment response, change in the level of disease-related biomarkers, and documentation of quality of life. The first patient is scheduled to be treated in April 2023.

For more information about DexTech, please contact:

Gösta Lundgren - CFO

DexTech Medical AB

Phone: +46 (0) 707104788

E-post: gosta.lundgren@dextechmedical.com

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on March 27, 2023.

DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to outlicense each drug candidate no later than after the completed phase II study. DexTech Medical AB is listed on Spotlight Stock Market.